Patrick John Finn Sells 6,239 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 6,239 shares of Twist Bioscience stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $278,259.40. Following the sale, the chief operating officer now directly owns 231,401 shares of the company’s stock, valued at approximately $10,320,484.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total value of $111,422.36.
• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The shares were sold at an average price of $43.09, for a total transaction of $97,426.49.
• On Wednesday, October 2nd, Patrick John Finn sold 6,865 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total transaction of $296,636.65.

Twist Bioscience Stock Down 0.3 %

Shares of TWST stock opened at $45.40 on Friday. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of -11.88 and a beta of 1.78. The business’s fifty day moving average is $43.69 and its 200 day moving average is $45.64. Twist Bioscience Co. has a twelve month low of $15.85 and a twelve month high of $60.90.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Intech Investment Management LLC purchased a new stake in Twist Bioscience in the third quarter worth about $714,000. Jennison Associates LLC increased its position in Twist Bioscience by 29.6% during the 3rd quarter. Jennison Associates LLC now owns 377,894 shares of the company’s stock valued at $17,073,000 after buying an additional 86,399 shares in the last quarter. Thrivent Financial for Lutherans purchased a new position in Twist Bioscience during the third quarter valued at $43,992,000. Chesapeake Capital Corp IL boosted its holdings in Twist Bioscience by 27.9% in the third quarter. Chesapeake Capital Corp IL now owns 6,176 shares of the company’s stock worth $287,000 after acquiring an additional 1,347 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in Twist Bioscience by 7.7% in the third quarter. Victory Capital Management Inc. now owns 331,809 shares of the company’s stock worth $14,991,000 after acquiring an additional 23,638 shares in the last quarter.

Wall Street Analysts Forecast Growth

TWST has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Barclays lowered their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Robert W. Baird raised their price target on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. Leerink Partners boosted their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Finally, Evercore ISI raised their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.